45 related articles for article (PubMed ID: 1813437)
1. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.
Rondelli I; Acerbi D; Ventura P
Int J Clin Pharmacol Res; 1991; 11(4):183-92. PubMed ID: 1813437
[TBL] [Abstract][Full Text] [Related]
2. Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure.
Viron B; De Meyer M; Le Liboux A; Frydman A; Maillard F; Mignon F; Gaillot J
Int Clin Psychopharmacol; 1990 Apr; 5 Suppl 2():95-104. PubMed ID: 2387982
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet.
Rohatagi S; Barrett JS; Sawyers W; Yu K; Morales RJ
Am J Ther; 1997; 4(7-8):229-38. PubMed ID: 10423615
[TBL] [Abstract][Full Text] [Related]
4. Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
Rohatagi S; Barrett JS
Am J Ther; 1997; 4(5-6):189-98. PubMed ID: 10423610
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of nicotine in kidney failure.
Molander L; Hansson A; Lunell E; Alainentalo L; Hoffmann M; Larsson R
Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
Danielson B; Querin S; LaRochelle P; Sultan E; Mouren M; Bryce T; Stepniewski JP; Lenfant B
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S50-9. PubMed ID: 7527102
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease.
Busch U; Molzahn M; Bozler G; Koss FW
Arzneimittelforschung; 1981; 31(9):1507-11. PubMed ID: 7197965
[TBL] [Abstract][Full Text] [Related]
9. Butofilolol pharmacokinetics in chronic renal insufficiency.
Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of iopamidol in adults with renal failure.
Corradi A; Menta R; Cambi V; Maccarini P; Cerutti R
Arzneimittelforschung; 1990 Jul; 40(7):830-2. PubMed ID: 2222559
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans.
Neugebauer G; Wittenbrink-Dix AM; Woelke-Seidl E; Kaufmann B; Ponton T; Dahmen W; Mosberg H; Nieder N; Besenfelder E
Arzneimittelforschung; 1989 Oct; 39(10A):1336-9. PubMed ID: 2576358
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study.
Nathan N; Debord J; Narcisse F; Dupuis JL; Lagarde M; Benevent D; Lachatre G; Feiss P
Acta Anaesthesiol Belg; 1993; 44(3):77-85. PubMed ID: 8310787
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate.
Chung HJ; Lee MG
Biopharm Drug Dispos; 2006 Oct; 27(7):345-51. PubMed ID: 16902944
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
Acerbi D; Poli G; Ventura P
Eur J Drug Metab Pharmacokinet; 1998; 23(2):172-7. PubMed ID: 9725477
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cicletanine in patients with impaired renal function.
Jungers P
Drugs Exp Clin Res; 1988; 14(2-3):189-94. PubMed ID: 3416723
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
[TBL] [Abstract][Full Text] [Related]
18. The plasma concentration and renal elimination of phenols in patients with chronic renal insufficiency.
Schück O; Vidláková M; Erben J; Nádvorniková H; Teplan V; Reitschlägerová V
Czech Med; 1989; 12(2):117-24. PubMed ID: 2504560
[TBL] [Abstract][Full Text] [Related]
19. Determination of a isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography.
Kim SH; Lee JS; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):313-24. PubMed ID: 9485525
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of alfentanil in chronic renal failure.
Chauvin M; Lebrault C; Levron JC; Duvaldestin P
Anesth Analg; 1987 Jan; 66(1):53-6. PubMed ID: 3099599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
